Furthermore, both in vivo and in vitro JAK2 inhibitors have demonstrated to reduce HNSCC proliferation in previous study [129]; Ruxolitinib, a JAK1/2 inhibitor approved for myelofibrosis, has being evaluated in operable HNSCC (NCT03153982). This evidence concerns the gene JAK1 and head and neck squamous cell carcinoma.